Hologic Announces European Launch of Genius™ Digital Diagnostics System for Cervical Cancer Screening

Powerful artificial intelligence combined with digital imaging designed to transform the screening process

Hologic, Inc. (Nasdaq: HOLX) announced today that its new Genius™ Digital Diagnostics System is now commercially available in Europe. The Genius Digital Diagnostics System is the next generation of cervical cancer screening that combines deep learning-based artificial intelligence (AI) with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells in women. It was developed to provide actionable insights, and improve workflow and lab efficiency, all with one goal in mind – to eradicate cervical cancer.

With the Genius Digital Diagnostics System, cutting-edge image analysis thoroughly interrogates every cell on a ThinPrep® Pap test image to curate a single view of the most clinically relevant objects. The new algorithm – GeniusTM Cervical AI – narrows tens of thousands of cells down to an AI-generated gallery, which arms healthcare providers with the critical information they need to guide earlier detection and better treatment decisions for the patients in their care.

“We strive to develop innovative solutions that meet our customers’ needs. We are delighted in the overwhelming positive feedback from the customers who have been the first in the world to use this technology,” said Andrew Pieprzyk, vice president, Strategic Development Diagnostics, International, Hologic. “The technology enhances the capabilities of individual laboratories and also has the potential to radically transform how cervical cancer screening is carried out, by enabling laboratories within the same network to collaborate across the world to manage the case load.”

Hologic has been working with leading laboratories in Europe to give them an early opportunity to evaluate the new system including ZotzKlimas Diagnostics Laboratories in Germany, where Founder, Dietmar Klimas, M.D., has led the review.

“As one of the largest labs in Germany, our main objective is to deliver accurate results to doctors and ultimately patients,” said Dr Klimas. “We were one of the first in the world to work with the Genius Digital Diagnostics system. The trial proved to me that this system can help my team to accurately process samples faster and more easily. We are continuing to use it following the trial.”

The Genius Digital Diagnostics System enables seamless and dynamic collaboration across laboratories within a network, connecting pathologists with remote review capabilities so each patient can benefit from the collective knowledge of geographically dispersed experts. Digital case review promises to enhance the experience for lab partners by improving workflow and accelerating review time.

Hologic now offers the first CE-marked comprehensive cervical cancer screening portfolio from sample collection to digital diagnosis.[i] The Genius Digital Diagnostics System consists of the GeniusTM Digital Imager for image acquisition, the GeniusTM Cervical AI algorithm for analyzing images, the GeniusTM Image Management Server (IMS) for storing images and the GeniusTMReview Station for case review. The complete system is scalable, designed to fit the present and future needs of laboratories.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”